Globally, cardiovascular and cerebrovascular diseases, exacerbated by the factor of inflammation, pose significant health challenges. The complex pathogenesis of these diseases involves intricate interactions between metabolic factors and inflammatory processes. Despite a well-understood metabolic aspect and established therapeutic strategies for cardiovascular and cerebrovascular diseases, the effective management and prevention of metabolic disorders in patients, particularly those exacerbated by inflammation, have become urgent issues with the growing patient population.
By integrating data from genomics, transcriptomics, proteomics, metabolomics, and now including immunomics, researchers have uncovered new biomarkers and potential drug targets. This integration provides a solid scientific foundation for early diagnosis, risk assessment, and personalized treatment of cardiovascular and cerebrovascular diseases, taking into account the inflammatory component.
Firstly, risk prediction models constructed based on multi-omics data, including immunomics, help stratify patients accurately according to risk factors and facilitate early intervention and treatment. Secondly, to enhance the effectiveness and safety of treatment, large-scale clinical randomized controlled trials are needed to assess the relationship between metabolic and inflammatory factors and different subtypes of cardiovascular and cerebrovascular diseases. These studies will lay a solid foundation for developing evidence-based medical guidelines and assist in optimizing the use of metabolic and anti-inflammatory factors in treatment. Additionally, the development of novel metabolic and anti-inflammatory drugs, especially those capable of correcting metabolic imbalances and modulating inflammatory responses at the multi-organ level, offers new hope for the treatment of cardiovascular and cerebrovascular diseases.
We invite you to submit manuscripts detailing your latest research findings in exploring novel metabolic markers, drug targets, and their interplay with inflammation in cardiovascular and cerebrovascular diseases using multi-omics technologies such as genomics, transcriptomics, proteomics, metabolomics, and immunomics. We welcome submissions of original research, brief research reports, reviews, mini-reviews, methodologies, perspectives, and opinion articles focused on, but not limited to, the following topics:
1. Constructing a comprehensive metabolic and inflammatory network for cardiovascular and cerebrovascular diseases by integrating omics data. Analyzing patient samples using metabolomics and immunomics to identify disease-related metabolites and immune markers, and validating their potential for clinical application in diagnosis, risk assessment, and prognosis.
2. Investigating the mechanisms of immune response in metabolic and inflammatory cardiovascular and cerebrovascular diseases, focusing on the roles of B and T cells, antibody production, and cytokine activity. Identifying immune markers, cytokines, and potential immunotherapeutic targets, such as cellular receptors or signaling pathways, for novel therapeutic strategies.
3. Integrating multi-omics data, including immunomics, to construct molecular networks in cardiovascular and cerebrovascular diseases. Utilizing bioinformatics and statistical methods to predict disease progression, treatment response, and the role of inflammation. Applying multi-omics data for drug design and the discovery of new therapeutic targets.
4. Translating laboratory-discovered metabolic markers, immune therapy targets, and their relationship with inflammation into clinical applications. Developing diagnostic kits, drugs, or vaccines, and conducting clinical trials to assess efficacy and safety. Exploring personalized medicine based on genetic, biomarker, and immunological profiles to tailor treatment for patients.
Please note: Manuscripts consisting solely of computational analysis of bioinformatics or public genomic or transcriptional databases without validation (independent cohort or in vitro or in vivo biological validation) are outside the scope of this section and are not accepted as part of this research topic. Manuscript dealing with traditional or complementary medicine without a very strong focus on immunological parameters are out of scope for this journal.
Globally, cardiovascular and cerebrovascular diseases, exacerbated by the factor of inflammation, pose significant health challenges. The complex pathogenesis of these diseases involves intricate interactions between metabolic factors and inflammatory processes. Despite a well-understood metabolic aspect and established therapeutic strategies for cardiovascular and cerebrovascular diseases, the effective management and prevention of metabolic disorders in patients, particularly those exacerbated by inflammation, have become urgent issues with the growing patient population.
By integrating data from genomics, transcriptomics, proteomics, metabolomics, and now including immunomics, researchers have uncovered new biomarkers and potential drug targets. This integration provides a solid scientific foundation for early diagnosis, risk assessment, and personalized treatment of cardiovascular and cerebrovascular diseases, taking into account the inflammatory component.
Firstly, risk prediction models constructed based on multi-omics data, including immunomics, help stratify patients accurately according to risk factors and facilitate early intervention and treatment. Secondly, to enhance the effectiveness and safety of treatment, large-scale clinical randomized controlled trials are needed to assess the relationship between metabolic and inflammatory factors and different subtypes of cardiovascular and cerebrovascular diseases. These studies will lay a solid foundation for developing evidence-based medical guidelines and assist in optimizing the use of metabolic and anti-inflammatory factors in treatment. Additionally, the development of novel metabolic and anti-inflammatory drugs, especially those capable of correcting metabolic imbalances and modulating inflammatory responses at the multi-organ level, offers new hope for the treatment of cardiovascular and cerebrovascular diseases.
We invite you to submit manuscripts detailing your latest research findings in exploring novel metabolic markers, drug targets, and their interplay with inflammation in cardiovascular and cerebrovascular diseases using multi-omics technologies such as genomics, transcriptomics, proteomics, metabolomics, and immunomics. We welcome submissions of original research, brief research reports, reviews, mini-reviews, methodologies, perspectives, and opinion articles focused on, but not limited to, the following topics:
1. Constructing a comprehensive metabolic and inflammatory network for cardiovascular and cerebrovascular diseases by integrating omics data. Analyzing patient samples using metabolomics and immunomics to identify disease-related metabolites and immune markers, and validating their potential for clinical application in diagnosis, risk assessment, and prognosis.
2. Investigating the mechanisms of immune response in metabolic and inflammatory cardiovascular and cerebrovascular diseases, focusing on the roles of B and T cells, antibody production, and cytokine activity. Identifying immune markers, cytokines, and potential immunotherapeutic targets, such as cellular receptors or signaling pathways, for novel therapeutic strategies.
3. Integrating multi-omics data, including immunomics, to construct molecular networks in cardiovascular and cerebrovascular diseases. Utilizing bioinformatics and statistical methods to predict disease progression, treatment response, and the role of inflammation. Applying multi-omics data for drug design and the discovery of new therapeutic targets.
4. Translating laboratory-discovered metabolic markers, immune therapy targets, and their relationship with inflammation into clinical applications. Developing diagnostic kits, drugs, or vaccines, and conducting clinical trials to assess efficacy and safety. Exploring personalized medicine based on genetic, biomarker, and immunological profiles to tailor treatment for patients.
Please note: Manuscripts consisting solely of computational analysis of bioinformatics or public genomic or transcriptional databases without validation (independent cohort or in vitro or in vivo biological validation) are outside the scope of this section and are not accepted as part of this research topic. Manuscript dealing with traditional or complementary medicine without a very strong focus on immunological parameters are out of scope for this journal.